TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26849996

Group type: EXPERIMENTAL
Intervention: I Move; a web‐based PA intervention based on SDT and MI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active Plus; a traditional web‐based PA intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study: 24832463

Group type: EXPERIMENTAL
Intervention: LOLA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 22266605

Group type: EXPERIMENTAL
Intervention: Biliary irradiation stent
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional biliary stent
Number of subjects: 23
Study: 19731311

Group type: EXPERIMENTAL
Intervention: Trocar guided transvaginal mesh
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colporraphy
Number of subjects: 50
Study: 18608057

Group type: EXPERIMENTAL
Intervention: Internet-based HIV behavioral intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (educational materials)
Number of subjects: 280
Study: 16043734

Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B)
Number of subjects: 163
Study: 11978675

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 11
Study: 10071170

Group type: EXPERIMENTAL
Intervention: Efamol Marine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7751891

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: VATH (vinblastine, doxorubicin, thiotepa, and halotestin)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: VATH alternating with CMFVP (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 491
Study: 2345394

Group type: EXPERIMENTAL
Intervention: 7 types of epidural catheters
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Hard catheter against resistance to insertion
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Soft catheter
Number of subjects: 1415
Study: 574352

Group type: EXPERIMENTAL
Intervention: Soy isolate-based formula supplemented with L-methionine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Soy isolate-based formula unsupplemented with methionine
Number of subjects: 19
Study: 31038991

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional surgical instrumentation (CSI)
Number of subjects: 50
Study: 28399873

Group type: EXPERIMENTAL
Intervention: Functional gait‐oriented mental practice combined with gait training (40 min, 3 times/week, for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-motor task mental practice
Number of subjects: 15
Study: 25836922

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24053549

Group type: EXPERIMENTAL
Intervention: Lifestyle Matters programme
Number of subjects: 268

Group type: COMPARATOR
Intervention: Routine access to health and social care (Control)
Number of subjects: 268
Study: 21834112

Group type: EXPERIMENTAL
Intervention: Hospitalist‐ACE service
Number of subjects: 217
Study: 19307271

Group type: EXPERIMENTAL
Intervention: Repeat prenatal corticosteroid treatment (weekly betamethasone)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 145
Study: 16680099

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Slit-lamp indirect ophthalmoscopy by specialists
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison of OCT and specialists
Number of subjects: 81
Study: 15053915

Group type: EXPERIMENTAL
Intervention: Experimental bonding system (Exp) with 10% ascorbic acid and 5% ferric chloride; conditioned with phosphoric acid, NaOCl, and Exp; bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panavia Fluoro Cement with AD gel (AD/Panavia); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Super‐Bond C&B (10‐3); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panavia Fluoro Cement (Panavia); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0

Group type: COMPARATOR
Intervention: All‐Bond 2 system (All‐Bond 2); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study: 11829219

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 157

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 157
Study: 9725481

Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg tablet administered after a standardized breakfast
Number of subjects: 12
Study: 7848346

Group type: EXPERIMENTAL
Intervention: Vita‐Gerin‐Geistlich (1 capsule/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3178294

Group type: EXPERIMENTAL
Intervention: Nasal breathing during 30-min exposure to approximately 0.4 ppm O3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral breathing during 30-min exposure to approximately 0.4 ppm O3
Number of subjects: 0
Study: 167583

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neomycin and Polymyxin B combination
Number of subjects: 120
Study: 31289351

Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 397
Study: 28296257

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg in 250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 26388067

Group type: EXPERIMENTAL
Intervention: Surgical removal of impacted lower third molars in overweight patients
Number of subjects: 560

Group type: COMPARATOR
Intervention: Surgical removal of impacted lower third molars in normal-weight patients
Number of subjects: 560
Study: 23948632

Group type: EXPERIMENTAL
Intervention: s-allele of the 5-HTTLPR
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: MDP patients
Number of subjects: 112
Study: 21631494

Group type: EXPERIMENTAL
Intervention: Sublingual feverfew/ginger
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17595032

Group type: EXPERIMENTAL
Intervention: Autologous Preparation Rich in Growth Factors (PRGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 0
Study: 16468084

Group type: EXPERIMENTAL
Intervention: NIH-CPSI total score
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NIH-CPSI pain score
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NIH-CPSI quality of life score
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NIH-CPSI urinary score
Number of subjects: 174
Study: 12956892

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 5 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 10 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 15 days
Number of subjects: 17
Study: 10855738

Group type: EXPERIMENTAL
Intervention: Trandolapril/verapamil (2 mg/180 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Trandolapril (2 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Verapamil (240 mg)
Number of subjects: 226
Study: 9115527

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus a 15‐minute tepid sponge bath
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 20
Study: 1288925

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (warming needle and point injection)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study: 2871418

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU capsules distributed twice, 1-3 months and 6 months after baseline)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 229
Study: 31086274

Group type: EXPERIMENTAL
Intervention: Paired corticospinal–motoneuronal stimulation (PCMS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (100 peripheral nerve stimuli)
Number of subjects: 11
Study: 29198731

Group type: EXPERIMENTAL
Intervention: Meloxicam (NSAID)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 27750250

Group type: EXPERIMENTAL
Intervention: Low-energy diet (6.0-8.0 MJ) - high carbohydrate
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-energy diet (6.0-8.0 MJ) - moderate carbohydrate with increased protein
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 87
Study: 24373754

Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 2.2 ml kg(‐1) (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 8 ml kg(‐1) (Group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 12 ml kg(‐1) (Group 3)
Number of subjects: 48
Study: 22839514

Group type: EXPERIMENTAL
Intervention: Quinapril 21.0±5 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Metoprolol succinate 87.7±7.6 mg/day
Number of subjects: 200
Study: 20370859

Group type: EXPERIMENTAL
Intervention: Fall prevention clinic
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 17514383

Group type: EXPERIMENTAL
Intervention: EBVS LigaSure V (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ultrasonic shears harmonic scalpel (HS) (group B)
Number of subjects: 24
Study: 15983321

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day)
Number of subjects: 14
Study: 12207676

Group type: EXPERIMENTAL
Intervention: Calcipotriol-narrow-band UVB
Number of subjects: 28

Group type: COMPARATOR
Intervention: Narrow-band UVB
Number of subjects: 28
Study: 10476942

Group type: EXPERIMENTAL
Intervention: nHuIFN-alpha 150 IU TID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8911977

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 577

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 577
Study: 1866749

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 220

Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 220
Study: 7169630

Group type: EXPERIMENTAL
Intervention: Stimulus fading
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stimulus delay
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reinforcement only
Number of subjects: 24
Study: 30704933

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 93

Group type: COMPARATOR
Intervention: CICC
Number of subjects: 93
Study: 30587273

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) using inverse variance weighted (IVW) method and MR-Egger
Number of subjects: 0
Study: 26948160

Group type: EXPERIMENTAL
Intervention: Motivational audiovisual condition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Neutral audiovisual condition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study: 23861004

Group type: EXPERIMENTAL
Intervention: Participants instructed to avoid thinking about nonemotional targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants instructed to think about nonemotional targets
Number of subjects: 0
Study: 22309471

Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral therapy (FCBT)
Number of subjects: 49
Study: 19171500

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125mg/d
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25mg/d
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50mg/d
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75mg/d
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 18254226

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy for 12 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy
Number of subjects: 49
Study: 16390021

Group type: COMPARATOR
Intervention: 185 MBq of 131I
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 370 MBq of 131I
Number of subjects: 59
Study: 9706947

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty without pneumatic tourniquet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total knee arthroplasty with pneumatic tourniquet
Number of subjects: 24
Study: 8588791

Group type: EXPERIMENTAL
Intervention: Double dose hyoscine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo hyoscine and placebo pyridostigmine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Double dose hyoscine and pyridostigmine
Number of subjects: 47
Study: 2089088

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 31
Study: 112475

Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg per day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30829892

Group type: EXPERIMENTAL
Intervention: High-fidelity training model for dynamic ONSD measurement using ETT cuff volumes of 0.1 mL, 0.2 mL, and 0.3 mL.
Number of subjects: 30
Study: 29927860

Group type: EXPERIMENTAL
Intervention: Annular Closure Device (ACD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Lumbar Discectomy (Control)
Number of subjects: 0
Study: 28928601

Group type: EXPERIMENTAL
Intervention: RVA pacing (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RVOT pacing (n = 30)
Number of subjects: 60
Study: 25428708

Group type: EXPERIMENTAL
Intervention: Cued memories (prioritized memory item)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncued memories (non-prioritized memory item)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No memory items prioritized by a retro-cue
Number of subjects: 0
Study: 25005893

Group type: EXPERIMENTAL
Intervention: 1× hydration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2× hydration
Number of subjects: 26

Group type: COMPARATOR
Intervention: no hydration
Number of subjects: 26
Study: 22024475

Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction program (MITP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study: 19387899

Group type: EXPERIMENTAL
Intervention: Information Communication Technology (ICT) guidance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional face-to-face guidance
Number of subjects: 52
Study: 17151807

Group type: EXPERIMENTAL
Intervention: 1200 GalU of alpha-galactosidase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 GalU of alpha-galactosidase
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14674932

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg oral, bedtime)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11892891

Group type: EXPERIMENTAL
Intervention: Declarative knowledge under explicit learning conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Declarative knowledge under implicit learning conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Declarative knowledge
Number of subjects: 0
Study: 9020283

Group type: EXPERIMENTAL
Intervention: Etoposide and carboplatin with GM-CSF (molgramostim)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 microg/kg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6 with GM-CSF
Number of subjects: 44
Study: 8490637

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioral treatment and desipramine
Number of subjects: 71

Group type: COMPARATOR
Intervention: High cluster B score
Number of subjects: 71
Study: 3829579

Group type: EXPERIMENTAL
Intervention: Meptazinol 140 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Meptazinol 280 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Meptazinol (therapeutic dose range)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine 7.5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine 15 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine 30 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30799638

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 302
Study: 29718354

Group type: EXPERIMENTAL
Intervention: BetterBirth Program (coaching targeting implementation of Checklist with data feedback and action planning)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BetterBirth Program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 120
Study: 27502703

Group type: EXPERIMENTAL
Intervention: Radiation dose of 59.4-60 Gy
Number of subjects: 33566

Group type: EXPERIMENTAL
Intervention: Radiation dose of 61-69 Gy
Number of subjects: 33566

Group type: EXPERIMENTAL
Intervention: Radiation dose of ≥70 Gy
Number of subjects: 33566

Group type: EXPERIMENTAL
Intervention: Radiation dose of 66 Gy
Number of subjects: 33566

Group type: EXPERIMENTAL
Intervention: Radiation dose of 70 Gy
Number of subjects: 33566

Group type: EXPERIMENTAL
Intervention: Radiation dose of ≥71 Gy
Number of subjects: 33566

Group type: COMPARATOR
Intervention: Comparison of 66 Gy vs ≥71 Gy
Number of subjects: 33566
Study: 26556393

Group type: EXPERIMENTAL
Intervention: Monophasic Pulsed Current (MPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Burst-Modulated Alternating Current (BMAC)
Number of subjects: 20
Study: 22999331

Group type: EXPERIMENTAL
Intervention: Threshold(®)IMT training, 5 times per week for 6 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 20510974

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 18388724

Group type: EXPERIMENTAL
Intervention: Fiberglass casts
Number of subjects: 34

Group type: COMPARATOR
Intervention: Plaster casts
Number of subjects: 34
Study: 12436219

Group type: EXPERIMENTAL
Intervention: Individual timing of blood counts
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard twice a week G-CSF prophylaxis
Number of subjects: 8
Study: 9579238

Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin without a meal (Day B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin with a standard meal (Day C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin 1.5 hours after a standard meal (Day D)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo with no meal (Day A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All active treatment days (B, C, D)
Number of subjects: 16
Study: 7699968

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg per day for three days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2566284

Group type: EXPERIMENTAL
Intervention: Vecuronium without glycopyrronium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 80
Study: 923185

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 16
Study: 31399245

Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Number of subjects: 362
Study: 27988297

Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (GSH) treatment for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing GGT activity in sputum
Number of subjects: 0
Study: 25858281

Group type: EXPERIMENTAL
Intervention: Walking and nutrition (W/N) group
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Walking (W) group
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 227
Study: 23711530

Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic therapy; n = 20
Number of subjects: 81

Group type: COMPARATOR
Intervention: No PCT guidance; n = 31
Number of subjects: 81
Study: 21841092

Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM) of warfarin therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Physician management of warfarin therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Patient self-management (PSM) and Physician management
Number of subjects: 11
Study: 18555238

Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist (GnRH‐a) flare-up protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 42
Study: 17165022

Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 14
Study: 15534050

Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi uptake in benign lesions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi uptake in carcinomas
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lesion size < 1 cm
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation with proliferative cellular activity, multidrug resistance expression, or receptor status
Number of subjects: 75
Study: 11172833

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 1 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 3 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (1, 3, or 5 mg)
Number of subjects: 48